*Clostridioides difficile* is an anaerobic, spore-forming, Gram-positive bacillus that was first isolated from the feces of healthy infants by Hall and O'Toole in 1935 \[[@CIT0001]\]. The incidence of *C. difficile* infection (CDI) has increased over the past 2 decades, making *C. difficile* the most common pathogen causing health care--associated infections in the United States \[[@CIT0002]\]. The ability of *C. difficile* to cause clinical disease in humans is dependent on toxin production. With few exceptions, all toxigenic strains of *C. difficile* identified in humans produce a cytotoxin, toxin B, and most coproduce an enterotoxin, toxin A \[[@CIT0007]\]. In addition, some strains produce a binary toxin, *Clostridium difficile* transferase (CDT), encoded by genes *cdtA* and *cdtB* \[[@CIT0008]\]. The recent epidemic ribotype 027 (RT 027) harbors binary toxin genes \[[@CIT0009]\], as do other ribotypes (eg, RT 019, 075, and 078) \[[@CIT0008], [@CIT0011], [@CIT0014]\]. Highly dependent on circulating strains, studies have demonstrated the prevalence of binary toxin strains infecting humans to range from 6% to 84% \[[@CIT0010], [@CIT0011], [@CIT0014], [@CIT0017]\]. Although controversial, the presence of binary toxin has been shown to increase the severity \[[@CIT0017]\], nonhome discharge \[[@CIT0022]\], mortality \[[@CIT0012], [@CIT0015], [@CIT0017], [@CIT0021]\], and recurrence of CDI \[[@CIT0011]\].

A recent clinical trial demonstrated increased mortality rates in patients with CDI and eosinopenia but was limited by a lack of data on binary toxin strains \[[@CIT0023]\]. In vitro and mouse models recently demonstrated that the binary toxin increases virulence by suppressing the protective effects of colonic eosinophilia, with an associated increase in the host inflammatory response \[[@CIT0024]\]. These effects are thought to be due to the indirect apoptosis of systemic eosinophils via increased recognition of binary toxin by the toll-like receptor 2 located on eosinophils \[[@CIT0024]\]. The relationship between binary toxin and eosinopenia to synergistically increase mortality has not been studied in humans.

Given this background, our research group has been conducting an ongoing clinical trial of patients with CDI for several years \[[@CIT0022]\]. As part of this study, leftover stool samples from hospitalized patients are collected for *C. difficile* growth and polymerase chain reaction (PCR) ribotyping \[[@CIT0025]\]. As we routinely collect clinical data on these patients, including results from hematologic blood draws and discharge status, we had the unique opportunity to study if patients with eosinopenia and binary toxin had increased likelihood of inpatient mortality compared with other groups. Our hypothesis was that CDI due to a binary toxin strain accompanied by peripheral eosinopenia would be associated with higher odds of inpatient mortality. To test our hypothesis, we conducted a large multicenter cohort study evaluating the association between inpatient mortality and CDI due to a binary toxin strain accompanied by eosinopenia. An ongoing collaboration with a co-investigator allowed us to confirm our results in an independent cohort of US veterans.

METHODS {#s1}
=======

Houston Cohort {#s2}
--------------

### Study Population {#s3}

This multicenter, retrospective cohort study was conducted using data available from an ongoing clinical study of patients with CDI hospitalized in 2 large health systems (13 hospitals in total) in the Houston, Texas area (years: 2015--2018). The study included all patients ≥18 years of age with CDI who had specimen ribotype data available. Patients were excluded if they did not have clinical or laboratory data available, their test result represented a test for cure, receiving corticosteroids greater than prednisone 5 mg per day, or they were neutropenic. The study was approved by the University of Houston Committee for the Protection of Human Subjects with a waiver of informed consent (IRB study 00000128).

### Definitions {#s4}

Patients were tested for CDI at the discretion of the treating physician and medical team. The standard-of-care diagnostic in the included facilities was a *C. difficile* nucleic acid amplification test (NAAT) or enzyme-linked immunosorbent assay (EIA) in patients with unexplained and new-onset diarrhea (≥3 unformed stools in 24 hours). Recurrent *C. difficile* infection and health care facility--onset CDI (HO-CDI) cases were defined by the Centers for Disease Control and Prevention multidrug-resistant organism and CDI module \[[@CIT0026]\]. Two episodes of CDI in the same patient were considered to be distinct events if they occurred \>8 weeks apart, meaning the same patient could be included more than once. Clinical definitions of CDI severity were defined per the 2017 Infectious Diseases Society of America and Society for Healthcare Epidemiology of America *C. difficile* guidelines \[[@CIT0027]\]. Admission and discharge location options included home, long-term care facility, another hospital, hospice, or death. The need for a higher level of care was determined by a trained abstractor and was defined as discharge to a facility offering higher-intensity medical and/or nursing services than residence before admission (eg, admitted from home and discharged to an SNF). Lastly, eosinopenia was defined as an eosinophil count of 0.0 cells/μL (0.0 cells\*10^9^/L), measured using hematologic blood draws obtained within 24 hours of stool collection.

### Covariates and Outcomes {#s5}

Medical records were reviewed retrospectively for demographic information, underlying comorbidities, laboratory data, and clinical outcomes. Notably, both health systems utilize a system-wide electronic health record (EHR) system, allowing medical data to be collected from the entire health system. Laboratory analytes measured at the time of CDI diagnosis (±24 hours) included white blood cell (WBC) count, eosinophil count, albumin level, and serum creatinine (SCr) level. The Charlson Comorbidity Index (CCI) score was calculated using comorbidities documented on or before the date of hospital admission \[[@CIT0028]\]. The primary study outcome was inpatient mortality. Secondary outcomes included 30-day recurrence, 90-day recurrence, intensive care unit admission within 48 hours of CDI diagnosis, colectomy within 30 days of CDI diagnosis, and a need for a higher level of care upon discharge.

### Sample Collection and Ribotyping {#s6}

Leftover stool samples from patients diagnosed with CDI were collected and brought to a centralized research laboratory at the University of Houston. Stool samples were then plated onto *C. difficile*--selective cefoxitin-cycloserine-fructose agar plates and anaerobically incubated for 48--72 hours. Colonies were identified as *C. difficile* by PCR. Fluorescent PCR ribotyping was performed as previously described \[[@CIT0025], [@CIT0029], [@CIT0030]\]. The library contains \>100 known ribotypes (<https://thewalklab.com/tools/>) but does not distinguish between ribotypes 053 and 163, ribotypes 014 and 020, and ribotypes 078 and 126; therefore, these are reported as combined ribotypes (eg, 053-163, 014-020, and 078-126). Binary toxin is present in RT 019, 027, 075, and 078--126 \[[@CIT0008]\].

Veterans' Cohort {#s7}
----------------

### Study Population, Definitions, Covariates, and Outcomes {#s8}

Data for the Veteran's cohort were obtained from the Department of Veterans Affairs Informatics and Computing Infrastructure, which includes administrative, clinical, laboratory, and pharmacy data repositories that are linked using unique patient identifiers. Patients were included if they were 18--89 years old and had any inpatient or outpatient International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code for CDI (008.45) plus a positive CDI stool test (eg, NAAT or EIA) during the visit or within 7 days of the visit from October 1, 2002, through September 30, 2014. Patients were excluded if they had an ICD-9-CM code for CDI in the year before cohort inclusion to select for primary cases. Patients were also excluded if they did not receive active CDI therapy or did not have complete laboratory data (eg, eosinophil count). The database was queried for hospitals that reported either RT 027 or binary toxin data in the EHR, most commonly due to use of the Expert *C. difficile*/Epi PCR diagnostic (Cepheid, Sunnyvale CA, USA), which reports binary toxin/ribotype 027 results. The University of Texas Health Science Center at San Antonio and the South Texas Veterans Health Care System Research and Development Committee institutional review boards, with a waiver of informed consent, approved the study (approval \#HSC20130473H).

Statistical Analysis {#s9}
--------------------

An eosinophil count reported as 0.0 cells/μL (0.0 cells\*10^9^/L) was the cutoff used to stratify the cohort. For baseline characteristic comparison, binary and categorical variables were compared using the χ ^2^ or Fisher exact test, whereas continuous variables were compared using the Student *t* test or Wilcoxon rank-sum test, depending on the data distribution. A logistic regression model was developed modeling inpatient mortality as a function of the available patient covariates based on methods recommended by Hosmer and Lemeshow \[[@CIT0031]\]. To prevent overfitting the model, covariates with a univariate Wald test *P* value \<.20 were chosen as candidates for the multivariable model. Following the fit of this model, each covariate was assessed again using the *P* value of its Wald statistic. Variables with a *P* \> .05 were removed, and the partial likelihood ratio test was used to compare the new, smaller model with the old model. Secondary outcomes were compared between cohorts by univariate comparison. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated. The cumulative probability of survival during 90 days of follow-up was estimated using the Kaplan-Meier procedure, whereas the groups were compared using the log-rank test. The time to death was defined as the number of days between CDI diagnosis and death from any cause on or before day 90. All *P* values were from 2-sided tests, and results were deemed statistically significant at *P* \< .05. All statistical analyses were performed using STATA, version 15.1 (StataCorp LLC, College Station, TX, USA), and RStudio (RStudio Inc., Boston, MA, USA).

RESULTS {#s10}
=======

Houston Cohort {#s11}
--------------

### Patient Characteristics {#s12}

A total of 3118 patients met the inclusion criteria; 2309 patients were missing clinical outcomes data, 110 patients had missing laboratory values (eosinophil count or SCr), 10 patients' tests represented a test for cure, and 1 patient's sample was EIA-negative. The final study cohort consisted of 688 patients from 13 institutions in 6 cities (132 had a baseline eosinophil count of 0.0 cells/µL \[0.0 cells\*10^9^/L\], and 556 had a baseline eosinophil count \>0.0 cells/µL \[0.0 cells\*10^9^/L\]) ([Figure 1](#F1){ref-type="fig"}). Clinical outcome data were most commonly missing due to patient hospitalization before an EHR change-over by the health system that prevented access to the clinical data. Demographic and baseline characteristics of the patients are shown in [Table 1](#T1){ref-type="table"}. The mean age of the cohort was 64 ± 18 years, and 389 (56%) were female. The median CCI score was 2, 244 (35%) of the cases were defined as HO-CDI, 70 (10%) patients were experiencing a CDI recurrence, and 172 (25%) had been diagnosed with CDI at some point in their past. Most baseline characteristics were similar between groups, but patients with eosinopenia had a higher median WBC count at CDI diagnosis and race/ethnicity proportions differed between groups.

###### 

Comparison of Patient Demographics, Comorbidities, and Laboratory Parameters Between Eosinophil Count Groups

                                Houston Cohort                                 Veterans' Cohort                       
  ----------------------------- ------------------- ------------------- ------ ------------------- ------------------ --------
  Age, mean (±SD), y            65.5 (18.7)         63.7 (17.7)         .32    67 (12)             66 (12)            .33
  Female, No. (%)               71 (53.8)           318 (57.2)          .48    3 (4.4)             38 (5.3)           .78
  Race/ethnicity, No. (%)                                               .04                                           
  White, non-Hispanic           94 (71.2)           320 (57.6)                 43 (67.2)           459 (65.9)         .84
  Black, non-Hispanic           18 (13.6)           114 (20.5)                 19 (29.7)           186 (26.7)         .61
  Hispanic                      14 (10.6)           98 (17.6)                  2 (3.1)             25 (3.6)           .84
  Asian                         2 (1.5)             7 (1.3)                    0 (0.0)             26 (3.7)           .03
  Other^a^                      4 (3.0)             17 (3.1)                                                          
  CCI, median (IQR)             2 (1--3)            2 (1--4)            .09    3 (2--5)            3 (1--6)           .79
  SOT, No. (%)                  8 (6.1)             57 (10.3)           .14    2 (3.0)             6 (0.8)            .16
  HSCT, No. (%)                 0 (0.0)             1 (0.2)             1.00   0 (0.0)             0 (0.0)            N/A
  WBC, median (IQR), cells/μL   12.3 (8.7--20.0)    10.7 (7.3--15.8)    .001   15.4 (10.5--22.0)   10.6 (7.4--15.1)   \<.001
  SCr, median (IQR), mg/dL      1.07 (0.78--1.70)   1.06 (0.75--2.00)   .88    1.4 (1.0--2.3)      1.2 (0.9--1.9)     .12
  Albumin, mean (±SD), g/dL     3.1 (0.8)           3.1 (0.7)           .98    2.7 (2.3--3.4)      2.9 (2.4--3.5)     .31
  Severe CDI, No. (%)           73 (55.3)           289 (52.0)          .49    61 (91.0)           512 (70.8)         \<.001
  Testing method, No. (%)                                               .78                                           N/A
  NAAT                          129 (97.7)          538 (96.8)                 67 (100.0)          723 (100.0)        
  EIA                           3 (2.3)             18 (3.2)                   0                   0                  
  HO-CDI, No. (%)               40 (30.3)           204 (36.7)          .17    56 (83.6)           450 (62.2)         \<.001
  Recurrent CDI, No. (%)^b^     16 (12.1)           54 (9.7)            .41    0 (0.0)             0 (0.0)            N/A
  History of CDI, No. (%)^b^    36 (27.3)           136 (24.5)          .50    0 (0.0)             0 (0.0)            N/A
  CDT + ribotype, No. (%)       14 (10.6)           95 (17.1)           .07    13 (19.4)           214 (29.6)         .07

Abbreviations: CCI, Charlson Comorbidity Index; CDI, *Clostridioides difficile* infection; CDT+, binary toxin--positive; EIA, enzyme-linked immunosorbent assay; HO-CDI, health care facility--onset CDI; HSCT, hematopoietic stem cell transplantation; IQR, interquartile range; NAAT, nucleic acid amplification test; SCr, serum creatinine; SOT, solid organ transplantation; WBC, white blood cell count.

Conversion factors: WBC (10^9^/L) = WBC (cells/μL)/1 000 000; albumin (g/L) = albumin (g/dL)/100; SCr (mg/dL) = SCr (μmol/L)/88.42.

^a^American Indian, Alaska Native, Native Hawaiian, Pacific Islander, other race/ethnicity, or ≥2 races/ethnicities.

^b^No patients with a history of CDI were included in the validation cohort.

![Patient selection flow chart, Houston cohort. Abbreviations: EIA, enzyme-linked immunosorbent assay; SCr, serum creatinine.](ofz552f0001){#F1}

### C. difficile Strain Characteristics {#s13}

The most commonly isolated ribotypes present in ≥10% of the sample included RT 014-020, 106, 027, and 002 ([Supplementary Table 1](#sup2){ref-type="supplementary-material"}). In total, 109 (16%) were binary toxin strains, of which RT 027 was the most common (n = 82). The proportion of CDI due to a binary toxin strain did not differ between those with eosinopenia and those with a measureable peripheral blood eosinophil count within 24 hours of CDI diagnosis (10.6% vs 17%; *P* = .07). The sensitivity and specificity of eosinopenia as a surrogate for binary toxin presence were 12.8% and 79.6%, respectively.

### Clinical Outcomes {#s14}

Fourteen patients both had eosinopenia and were infected with a binary toxin strain. In univariate analysis, both eosinopenia (OR, 2.5; 95% CI, 1.1--5.4; *P* = .03) and infection with a binary toxin strain (OR, 3.7; 95% CI, 1.7--8.2; *P* = .01) were associated with inpatient mortality. However, the combination of CDI due to a binary toxin strain and eosinopenia was associated with a higher odds of inpatient mortality (OR, 10.8; 95% CI, 3.2--37.0; *P* \< .001). Patients were stratified into 4 groups: 1) binary toxin--positive with eosinopenia, 2) binary toxin--positive without eosinopenia, 3) binary toxin--negative with eosinopenia, and 4) binary toxin--negative without eosinopenia ([Figure 2](#F2){ref-type="fig"}). Inpatient mortality was highest for group 1 compared with all other groups (28.6% vs 7.4%, 5.1%, and 2.4%, respectively; *P* \< .001). Using Kaplan-Meier survival curves, time to death was also significantly shorter in patients with CDI due to a binary toxin strain and concomitant eosinopenia compared with all other groups (*P* = .03) ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Secondary outcomes did not differ significantly between groups ([Table 2](#T2){ref-type="table"}).

###### 

Stratified Univariate Analysis of Primary and Secondary Outcomes

  Outcomes                           Eosinopenia/CDT Present   Eosinopenia/CDT Present   Eosinopenia/CDT Present   Eosinopenia/CDT Present
  ---------------------------------- ------------------------- ------------------------- ------------------------- -------------------------
  Inpatient mortality, No. (%)       4 (28.6)                  7 (7.4)                   6 (5.1)                   11 (2.4)
  30-d recurrence, No. (%)           0 (0.0)                   5 (5.3)                   3 (2.5)                   22 (4.8)
  90-d recurrence, No. (%)           3 (21.4)                  20 (21.1)                 5 (4.2)                   55 (11.9)
  ICU admission, No. (%)             4 (28.6)                  13 (13.7)                 24 (20.3)                 57 (12.4)
  Higher LOC at discharge, No. (%)   7 (50)                    23 (24.2)                 44 (37.3)                 128 (27.8)
  Colectomy, No. (%)                 0 (0.0)                   0 (0.0)                   3 (2.5)                   4 (0.9)
  Veteran's Cohort                   Yes/Yes (n = 13)          No/Yes (n = 214)          Yes/No (n = 54)           No/No (n = 509)
  Inpatient mortality, No. (%)       5 (38.5)                  25 (11.7)                 7 (13.0)                  45 (8.8)
  30-d recurrence, No. (%)           1 (7.7)                   8 (3.7)                   0 (0.0)                   17 (3.3)
  90-d recurrence, No. (%)           3 (23.1)                  13 (6.1)                  0 (0.0)                   26 (5.1)
  ICU admission, No. (%)             0 (0.0)                   9 (4.2)                   1 (1.9)                   7 (1.4)
  Higher LOC at discharge, No. (%)   8 (66.7)                  54 (29.7)                 16 (32.0)                 88 (19.5)
  Colectomy, No. (%)                 0 (0.0)                   0 (0.0)                   0 (0.0)                   0 (0.0)

Abbreviations: CDT, binary toxin; ICU, intensive care unit; LOC, level of care.

![Infection with a binary toxin strain and eosinopenia was associated with increased inpatient mortality in both cohorts (*P* \< .001, each). Abbreviation: CDT, binary toxin.](ofz552f0002){#F2}

Using a multivariable model that adjusted for CCI score, WBC count, and serum albumin level, CDI due to a binary toxin strain with concomitant eosinopenia remained an independent predictor of inpatient mortality (OR, 7.8; 95% CI, 1.9--33.2; *P* = .005) ([Table 3](#T3){ref-type="table"}).

###### 

Univariate and Multivariable Analysis for Predictors of Inpatient Mortality Post--*Clostridioides difficile* Infection Diagnosis

                      Houston Cohort                                            Validation Cohort                                
  ------------------- ------------------- -------- ------------------- -------- ------------------- -------- ------------------- --------
  Eosinopenia + CDT   10.8 (3.2--37.0)    \<.001   7.8 (1.9--33.2)     .005     5.7 (1.8--17.8)     .003     6.1 (1.5--23.9)     .009
  Age, y              1.02 (0.99--1.04)   .14                                   1.01 (0.99--1.03)   .19                          
  CCI                 1.19 (1.02--1.39)   .02      1.23 (1.01--1.48)   .04      1.11 (1.04--1.19)   .002     1.09 (1.01--1.17)   .02
  SOT                 0.73 (0.17--3.14)   .67                                   9.0 (2.2--36.8)     .002                         
  WBC, cells/μL       1.05 (1.03--1.08)   \<.001   1.03 (1.00--1.06)   .02      1.02 (1.01--1.04)   .005     1.01 (0.99--1.03)   .18
  SCr, mg/dL          1.02 (0.88--1.19)   .76                                   0.96 (0.81--1.15)   .67                          
  Albumin, g/dL       0.15 (0.07--0.33)   \<.001   0.18 (0.08--0.43)   \<.001   0.48 (0.34--0.68)   \<.001   0.53 (0.37--0.77)   \<.001
  Severe CDI          1.65 (0.75--3.64)   .21                                   17.4 (4.3--71.6)    \<.001                       
  HO-CDI              2.95 (1.36--6.40)   .01                                   0.91 (0.57--1.47)   .71                          
  History of CDI^a^   0.49 (0.17--1.43)   .19                                                                                    

Abbreviations: CCI, Charlson Comorbidity Index; CDI, *Clostridioides difficile* infection; CDT, binary toxin; CI, confidence interval; HO-CDI, health care facility--onset CDI; OR, odds ratio; SCr, serum creatinine; SOT, solid organ transplantation; WBC, white blood cell count.

^a^No patients with a history of CDI were included in the validation cohort.

Veterans' Cohort {#s15}
----------------

A total of 26 149 veterans with CDI were included, of whom 790 had eosinophil and RT 027 (n = 322) or binary toxin (n = 468) laboratory data available in the EHR ([Table 1](#T1){ref-type="table"}). The mean age of the cohort was 66 ± 12 years, and 749 (95%) were male. The median CCI score was 3, 506 (64%) of the cases were defined as HO-CDI, 0 (0%) patients were experiencing a CDI recurrence, and 0 (0%) had been diagnosed with CDI at some point in their past. Patients were once again stratified into 4 groups: 1) binary toxin--positive with eosinopenia, 2) binary toxin--positive without eosinopenia, 3) binary toxin--negative with eosinopenia, and 4) binary toxin--negative without eosinopenia ([Figure 2](#F2){ref-type="fig"}). Thirteen patients both had eosinopenia and were infected with a binary toxin strain. Inpatient mortality was highest for group 1 compared with all other groups (38.5% vs 11.7%, 13.0%, and 8.8%, respectively). In univariate analysis, eosinopenia was associated with inpatient mortality (OR, 2.0; 95% CI, 1.0--3.9), whereas CDI due to a binary toxin strain was not. However, the combination of CDI due to a binary toxin strain and eosinopenia was a stronger predictor of mortality (OR, 5.7; 95% CI, 1.8--17.8). Secondary outcomes were similar to the results from the Houston cohort ([Table 2](#T2){ref-type="table"}).

In the multivariable model, the combination of CDI due to a binary toxin strain and eosinopenia remained an independent predictor of inpatient mortality after controlling for CCI score, WBC count, and serum albumin level (OR, 6.1; 95% CI, 1.5--23.9) ([Table 3](#T3){ref-type="table"}).

DISCUSSION {#s16}
==========

*C. difficile* transferase, also known as the binary toxin, is present in the major hypervirulent *C. difficile* strains including RT 027 and 078 \[[@CIT0008], [@CIT0009], [@CIT0011]\]. Recent in vitro and animal models have shown that the binary toxin induces a pathogenic host inflammatory response characterized by the suppression of colonic eosinophils and increased apoptosis of systemic eosinophils \[[@CIT0024]\]. However, outcomes associated with CDI due to a binary toxin strain and concomitant eosinopenia have not been studied in humans. We hypothesized that inpatient mortality would be higher in patients with CDI due to a binary toxin strain and concomitant eosinopenia compared with all other groups. Using 2 large, independent data sets, we demonstrated that the combination of CDI due to a binary toxin strain and eosinopenia led to a significantly greater odds of inpatient mortality. Patients infected with a binary toxin strain and concomitant eosinopenia were nearly 8 times more likely to die as an inpatient than patients who did not meet these criteria. The strengths of this study include its large, multicenter sample and *C. difficile* strain characterization by PCR ribotyping. We were also able to control for multiple patient characteristics known to confound CDI outcome by collecting a comprehensive list of relevant covariates. Furthermore, having 2 independent databases allowed us to confirm our results. Eosinopenia in the context of infection was first described in 1893 \[[@CIT0032]\] and is a result of migration of eosinophils to the site of infection during the acute phase of inflammation \[[@CIT0033]\]. Although the optimal cutoff to define a low eosinophil count is controversial, eosinopenia has been considered a criterion for systemic inflammatory response syndrome (SIRS) \[[@CIT0034]\]. Patients with eosinopenia associated with infections are more likely to present with more severe disease and increased likelihood of poor outcomes, including mortality. Our results support this observation. However, the fact that mortality was significantly increased in patients infected with binary toxin strains and eosinopenia, compared with patients with eosinopenia and other strains, supports our hypothesis of a synergy between the 2 variables.

Causality should not be inferred from these studies but raises important hypotheses for future prospective cohort studies. For example, the binary toxin may simply be a surrogate marker of other virulence traits of *C. difficile*. As eosinophil counts are readily available from routine complete blood counts collected from hospitalized patients, it would be relatively straightforward to identify patients with eosinopenia and CDI in real time. Several commercially available CDI diagnostics use PCR to detect the specific genes that encode for the binary toxin, allowing for prospective validation of the results observed in this study. Our study has a number of limitations. First, we chose an absolute cutoff to define eosinopenia to directly compare our results with the only other human trial \[[@CIT0023]\]. Our sample size was not large enough to explore an optimized cutoff, and this will need to be evaluated in future studies. Second, we chose to collect and analyze eosinopenia at a single time point within 24 hours of stool collection. Whether resolution of eosinopenia can be used as a prognostic marker of clinical response in CDI will require further study. Third, clinical data were obtained from the EHR as a secondary database analysis, and our results should be further validated using a prospective, multicenter study design. Although our primary objective was available for all patients, some of our secondary outcomes, such as 30- and 90-day recurrence, may have been underestimated. We did not evaluate binary toxin production or its biological activity, but rather assumed that all RT 019, 027, 075, and 078-126 isolates harbored genes capable of producing biologically active proteins, as previously demonstrated \[[@CIT0014]\]. Eosinopenia is associated with other chronic medical conditions such as trauma, stroke, and others. Our study lacks the sample size to correctly assess for the confounding of other medical conditions to influence these results. Lastly, these results demonstrate an association between the variables, and causality should not be inferred.

In conclusion, the combination of eosinopenia and CDI due to a binary toxin strain was correlated with increased mortality in hospitalized patients from 2 independent cohorts. Prospective studies should be performed to further study this important subset of patients at the time of CDI diagnosis.

Supplementary Data {#s17}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

###### 

Click here for additional data file.

###### 

Click here for additional data file.
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